PDI enters deal to sell cardiology drug

Share this article:
Contract sales firm PDI said it inked a one-year contract sales agreement for a cardiology drug with an unnamed “top-10 pharmaceutical company.” The initiative, expected to bring in $13 million in revenue, will target primary care physicians and cardiologists and was scheduled to get underway beginning April 2. The announcement is viewed as needed boost for PDI, which last month announced a decision by a “large pharmaceutical company” client not to renew a $35 million contract sales engagement with the firm. PDI previously expected that one-year deal, which expires May 12, to be extended through the end of 2007. PDI had 4 major contract losses during the past 12 months, as many drugmakers decided to re-evaluate sales force strategies. In October, GlaxoSmithKline chose not to renew its 2007 sales agreement with the firm – a deal representing as much as $70 million in annual revenue. Also in October, Sanofi-Aventis ended a $20 million sales engagement with PDI. And in March 2006, AstraZeneca discontinued its fee-for-service agreements with the contract sales firm, after previously working with PDI for 12 years. That termination affected approximately 800 field reps and impacted $65 to $70 million of PDI’s revenue.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...